Business Wire

International HIV Experts Call for Focus on Quality of Life Beyond Viral Suppression

Share

The Janssen Pharmaceutical Companies of Johnson & Johnson announces the first consensus white paper to be published by an esteemed group of experts who have come together to launch the “Moving Fourth” initiative. The initiative aims to tackle HIV-related health challenges faced by people living with HIV (PLWHIV), such as associated mental and physical co-morbidities, mental health issues, financial stresses and potential HIV-related stigma. The launch took place at the 17th European AIDS Conference in Basel, 6-9 November 2019.

Recommendations in the white paper, which have been summarised in AIDS Reviews , 1 focus on a new HIV care framework - Health Goals for Me. The recommendations were developed to support an holistic and individualised long-term treatment approach that goes beyond viral load and CD4 count, to assess health-related quality of life. Designed to empower healthcare professionals and PLWHIV to collaborate and mutually agree on objectives for care beyond viral suppression, the framework is comprised of a continuous cycle of ‘ask and measure’, ‘feedback and discussion’, and ‘intervention’.

“It is a pivotal moment in HIV,” said Dr Giovanni Guaraldi,* Chair of the Moving Fourth Expert Committee and Associate Professor of Infectious Disease and Head of the Modena HIV Metabolic Clinic (MHMC), Italy, in launching the group’s first paper. “Pioneering research means the disease is now viewed as a chronic condition. However, this brings new challenges relating to long-term health; as increasing numbers of people navigate their lives beyond viral suppression and look towards improved quality of life. Health Goals for Me should become an intrinsic part of HIV care in the future.”

This international, expert alignment represents a pathway to achieving the ‘fourth 90’, a goal that builds on the United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 treatment target.2 Through Health Goals for Me, the Moving Fourth Expert Committee aims to increase focus on taking an individualised long-term approach to patient care, which forms the basis of our continued work to develop practical tools which can help improve health-related quality of life for PLWHIV.

The UNAIDS proposed the ambitious 90-90-90 treatment plan in 2014 to end the AIDS epidemic: to diagnose 90% of all HIV-positive persons; provide antiretroviral therapy (ART) to 90% of those diagnosed; and to achieve viral suppression for 90% of those treated by 2020. These targets, however, do not cover other HIV-related health challenges faced by people living with HIV.

Mario Cascio,* Former-Chair of European AIDS Treatment Group (EATG), Italy, who lives with HIV and is a member of the expert committee said: “Treatment guidelines and policy for HIV are much the same as when it was a fatal disease. Despite HIV being considered a chronic condition, many people are suffering with the day-to-day impact of the disease, such as continued stigma, discrimination and health conditions experienced after many years of living with HIV. This international consensus represents an important first step to improve care beyond viral load and ultimately improve the lives of people living with HIV.”

“The Moving Fourth steering committee was convened to establish a way in which the ‘fourth 90’ can be achieved,” said Allitia diBernardo, Europe, Middle East and Africa Infectious Diseases and Vaccines Therapeutic Area Lead, Janssen-Cilag International NV. “The ultimate aim of this initiative is to provide clear, detailed guidelines and tools that support a holistic, individualised, long-term treatment approach for PLWHIV that goes beyond viral load and CD4 count. At Janssen we recognise that, despite progress made, HIV remains one of the greatest global health threats of our time. We won’t stop until we end HIV.”

The Moving Fourth steering committee members are:

  • Dr Giovanni GUARALDI (Chair), Associate Professor of Infectious Disease and Head of the Modena HIV Metabolic Clinic (MHMC), Italy
  • Dr Joop ARENDS, Internist, Associate Professor of Infectious Disease and Infectious Diseases Physician, Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, The Netherlands
  • Dr Thomas BUHK, Internist, Infectiologist, Centers for Infectious Diseases in Hamburg (ICH-Hamburg), Germany
  • Mario CASCIO Former-Chair, European AIDS Treatment Group (EATG), Italy
  • Dr Adrian CURRAN, Internist, Infectious Disease Specialist, Department of Infectious Diseases, Vall d’Hebron University Hospital, Barcelona, Spain
  • Dr Eugenio TEOFILO, Internist, Department of Internal Medicine at Hospital Dos Capuchos, Lisboa, Portugal
  • Dr Guido VAN DEN BERK, Internist, Infectious Disease Specialist, Department of Internal Medicine, OLVG, City Hospital of Greater Amsterdam, The Netherlands
  • Christian VERGER, Chair of the Grand Est region, Board member, AIDES-France, France

END

*Spokespeople involved have not been paid for media work. Dr. Giovanni Guaraldi reports personal fees from Janssen.

The White Paper was sponsored by Janssen-Cilag International NV one of the Pharmaceutical Companies of Johnson & Johnson. Each author received remuneration for the writing of the article and the fee for a medical writer was covered by Janssen. The views expressed are, however, the views of the authors and do not represent the views of Janssen.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Learn more at www.janssen.com/emea/. Follow us at www.twitter.com/JanssenEMEA.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, regarding a new white paper which outlines an HIV management framework designed to help end the AIDS epidemic. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen-Cilag International NV, or any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

CP-120070

November 2019

# # #

1 Giovanni G, Joop A, Thomas B, et al. 'Moving fourth’: a Vision Towards Achieving Healthy Living with HIV Beyond Viral Suppression. AIDS Reviews. 2019; 21(3).

2 UNAIDS. 90-90-90. Published 2014. An ambitious treatment target to help end the AIDS epidemic. Available from: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. [Last accessed: November 2019].

Contact information

Media Contact:
Sarah Smith
+44 7920 082012
SSmith49@ITS.JNJ.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan7.8.2020 12:28:00 EESTPress release

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200807005160/en/ “Takeda’s leading position in Japan, technical expertise,

SES S.A.: Half Year 2020 Results7.8.2020 08:30:00 EESTPress release

SES S.A. announced financial results for the six months ended 30 June 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806006164/en/ SES S.A.: Half Year 2020 Results (Photo: Business Wire) Solid H1 performance in line with expectations and continued underlying growth in Networks of +7.1% year-on-year(1,2) Revenue of EUR 947.5 million, -1.5% as reported with underlying revenue 2.4%(1,2) lower than H1 2019 Adjusted EBITDA(3) of EUR 582.0 million, -2.3% as reported (-3.5% at constant FX(2)) compared with H1 2019 and representing an Adjusted EBITDA(3) margin of 61.4% including a 2.2% year-on-year reduction in recurring operating expenses Limited COVID-19 impact in H1 reflecting business resilience with measures in place to mitigate increased headwinds in H2 2020 Updated FY 2020 group revenue outlook to EUR 1,860 - 1,900 million(4) in view of expected COVID-19 related revenue development FY 2020 Adjusted EBITDA(3) outlook

Western Union Stands in Solidarity with Lebanon6.8.2020 23:47:00 EESTPress release

Western Union, a leader in cross-border, cross-currency money movement and payments, today announced that it is offering zero-feei international money transfers paid out in U.S. dollars to Lebanon, as the country grapples with its recent tragedy amidst other economic and pandemic related threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806006068/en/ Western Union Stands in Solidarity with Lebanon; Money Transfers to Lebanon Zero-Fee Paid out in US Dollars (Graphic: Business Wire) “We stand in solidarity with the people of Lebanon as they confront this latest tragedy following the horrific explosion in Beirut on August 4. Our thoughts and prayers are with families of those injured and have lost their lives,” said Jean Claude Farah, President, Global Network, Western Union. Farah said: “We know the people of Lebanon will stand strong as they grapple with this latest issue amidst other pressures of economic and COVID-

Pacific Drilling Announces Second-Quarter 2020 Results; Pacific Sharav Awarded a New 10-Well Contract in U.S. Gulf of Mexico6.8.2020 23:04:00 EESTPress release

Pacific Drilling S.A. (NYSE: PACD) (“Pacific Drilling” or the “Company”) today reported results for the second quarter of 2020. Net loss for second-quarter 2020 was $87.4 million or $1.16 per diluted share, compared to net loss of $61.0 million or $0.81 per diluted share in first-quarter 2020. Pacific Drilling CEO Bernie Wolford commented, “In the second quarter, our crews and leadership continued to exemplify our commitment to safe and efficient operations, including adopting measures to manage risks associated with COVID-19 transmission, delivering exceptional results for our clients, efficiently preserving the value of our assets and significantly reducing overhead costs.” Mr. Wolford continued, “Although oil prices began to rebound during the second quarter, clients have generally reduced their drilling investments, as evidenced by Equinor’s decision to cancel the previously exercised third firm well for Pacific Khamsin, and Murphy’s decision to cancel the two well Mexico contract

Andersen Global Enters into Collaboration Agreement with CFA Afrique in Burkina Faso6.8.2020 16:30:00 EESTPress release

Andersen Global continues its West African expansion via a Collaboration Agreement with CFA Afrique, a tax and legal firm in Ouagadougou, marking the organization’s debut in Burkina Faso and further demonstrating Andersen Global’s growing presence on the African continent. Founded in 2004 and led by Office Managing Director Brahima Guire, CFA Afrique has grown to include nearly 20 total professionals advising a multitude of clients both regionally and internationally. The firm provides a variety of tax and legal services including tax consultancy and advisory, tax compliance, transfer pricing, corporate and commercial law and tax structuring. “Providing our clients with a tailor-made approach and the best-in-class solutions are our top priorities,” Brahima said. “Andersen Global’s expansion strategy and focus on providing clients with quality tax and legal services strengthens our competitive edge and will allow us to better serve our cross-border clientele. We look forward to seamless

New Conviva Data Shows Significant Drop in Ad Demand Despite Quality Improvements; Streaming Growth Normalizing After Pandemic Peak6.8.2020 16:00:00 EESTPress release

Conviva, the leader in global streaming media intelligence, released its quarterly State of Streaming report for Q2 2020 today, showing streaming video advertising saw a sharp decline in the past quarter with ad attempts in Q2 down 28% globally and 22% in the U.S. as compared to Q1 2020. The report also details the impact of COVID-19 with expanded regional benchmarks illustrating that while streaming continues to grow overall, it slowed in May and June as compared to its height in April when shelter-in-place orders drove streaming viewing up 81% year over year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200806005191/en/ Conviva's State of Streaming Q2 Report (Graphic: Business Wire) Ad Demand Drops while Quality Improves While advertising demand dropped in Q2, due in part to a lack of sports, streaming ads saw significant improvements in overall quality. Viewers spent 38% less time waiting for an ad to start in Q2 as com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom